上海凯宝：获得药物临床试验批准通知书

Core Viewpoint - Shanghai Kaibao (300039) has received approval from the National Medical Products Administration for the clinical trial of its drug KBZ24020, aimed at treating acute ischemic stroke [1] Company Summary - The drug KBZ24020 has been granted a clinical trial approval, indicating that the application meets the necessary requirements for drug registration [1] - The company is required to further refine the clinical trial protocol before commencing the trials [1] Industry Summary - The approval of KBZ24020 for clinical trials represents a significant step in the development of treatments for acute ischemic stroke, a critical area in the pharmaceutical industry [1]